RAPT Therapeutics (RAPT) Equity Ratio (2020 - 2024)
Historic Equity Ratio for Therapeutics (RAPT) over the last 5 years, with Q3 2024 value amounting to 0.88.
- Therapeutics' Equity Ratio rose 177.03% to 0.88 in Q3 2024 from the same period last year, while for Sep 2024 it was 0.88, marking a year-over-year increase of 177.03%. This contributed to the annual value of 0.85 for FY2023, which is 788.89% down from last year.
- Per Therapeutics' latest filing, its Equity Ratio stood at 0.88 for Q3 2024, which was up 177.03% from 0.86 recorded in Q2 2024.
- In the past 5 years, Therapeutics' Equity Ratio ranged from a high of 0.94 in Q2 2021 and a low of 0.84 during Q1 2024
- For the 5-year period, Therapeutics' Equity Ratio averaged around 0.89, with its median value being 0.88 (2024).
- Its Equity Ratio has fluctuated over the past 5 years, first surged by 879.41% in 2021, then plummeted by 788.89% in 2023.
- Therapeutics' Equity Ratio (Quarter) stood at 0.88 in 2020, then grew by 7.15% to 0.94 in 2021, then dropped by 1.85% to 0.92 in 2022, then dropped by 7.89% to 0.85 in 2023, then grew by 3.8% to 0.88 in 2024.
- Its Equity Ratio was 0.88 in Q3 2024, compared to 0.86 in Q2 2024 and 0.84 in Q1 2024.